. 2016 Nov 16;18:113. doi: 10.1186/s13058-016-0770-9

Table 3.

Relationship between nuclear ADA3 and nuclear c-MYC co-expression combinatorial phenotypic groups with molecular biomarker status within the whole unselected invasive breast cancer series (n = 588 cases)

		ADA3^low C MYC^low N (%)	ADA3^high C MYC^low N (%)	ADA3^low C MYC^high N (%)	ADA3^high C MYC^high N (%)	Significance
		ADA3^low C MYC^low N (%)	ADA3^high C MYC^low N (%)	ADA3^low C MYC^high N (%)	ADA3^high C MYC^high N (%)	X ²	P
ER Status	Negative	59 (39.6)	12 (8.1)	56 (37.6)	22 (14.8)	25.800	<0.001
ER Status	Positive	113 (26.0)	56 (12.9)	121 (27.9)	144 (33.2)	25.800	<0.001
PR Status	Negative	78 (36.0)	25 (10.3)	74 (30.6)	56 (23.1)	12.803	0.005
PR Status	Positive	79 (23.7)	43 (12.9)	102 (30.5)	110 (32.9)	12.803	0.005
HER2 Status*	Negative	6 (54.5)	2 (18.2)	1 (9.1)	2 (18.2)	21.743	0.010
HER2 Status*	Positive	132 (27.0)	55 (11.2)	152 (31.1)	150 (30.7)	21.743	0.010
Molecular Subtype	Luminal	99 (25.4)	49 (12.6)	110 (28.3)	131 (33.7)	25.405	<0.001
	HER2 Positive	34 (40.0)	10 (11.8)	24 (28.2)	17 (20.0)
	Triple Negative	38 (36.2)	7 (6.7)	43 (41.0)	17 (16.2)
Ki67 labelling** Index	Low	42 (23.0)	27 (14.8)	40 (21.9)	74 (40.4)	22.081	<0.001
Ki67 labelling** Index	High	83 (29.9)	30 (10.8)	101 (36.3)	64 (23.0)	22.081	<0.001
p27	Low	114 (38.8)	33(11.2)	89 (30.3)	58 (19.7)	38.276	<0.001
p27	High	40 (16.7)	33 (13.8)	77(32.1)	90 (37.5)	38.276	<0.001

*HER2 Status was assessed using American Society of Clinical Oncology/College of American Pathologists Guidelines Recommendations for HER2 Testing in Breast Cancer and Equivocal (2+) HER2+ cases were confirmed by FISH/CISH. ** Ki67 labelling index dichotomized at 14% according to St Galen consensus guidelines 2013

Analysis within the whole unselected invasive breast cancer series with respect to receptor status, molecular subtype, Ki67 labeling index, and p27 demonstrated a statistically significant correlation across the four groups